Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

AMBI $15.34 7.1400 +87.07%
CLVS $48.08 5.5900 +13.16%
CNDO $2.04 0.2200 +12.09%
IMMU $3.84 0.3200 +9.09%
CBMG $20.97 1.7320 +9.00%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

KPTI $38.38 -3.7200 -8.84%
SGEN $38.39 -2.9800 -7.20%
ECYT $6.99 -0.3500 -4.77%
VRML $1.83 -0.0900 -4.69%
CLDX $13.69 -0.6600 -4.60%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

FDA Advisory Panel Offers Cautious Support For Polypill

(Forbes) Sept 10, 2014 - The controversial polypill took one step closer to reaching the US market after receiving a mostly positive reception from the FDA’s Cardiovascular and Renal Drugs Advisory Committee on Wednesday.
read article 

Meet the Newest FDA-Approved Prescription Weight-Loss Drug: Contrave

(Washington Post/To Your Health) Sept 11, 2014 - The Food and Drug Administration has approved the latest prescription diet pill, Contrave, which is a combination of two previously FDA-approved drugs that treat addiction and depression.
read article (free registration required) 

Philips, IBA Strike Partnership Deal For Cancer Centres

(Reuters) Sept 11, 2014 - Philips and Belgium's Ion Beam Applications announced a partnership on Thursday designed to combine IBA's cancer-therapy technology with Philips' medical imaging systems.
read article 

Thyroid Cancer Rates in Pennsylvania Rising Faster Than Rest of Country

(Penn State News) Sept 10, 2014 - Incidence of thyroid cancer is rising faster in Pennsylvania than in the rest of the United States, according to Penn State College of Medicine researchers.
read article  

Medicare Bundled Payments Initiative and Oncology Care

(JD Supra/Foley & Lardner LLP) Sept 10, 2014 - According to Modern Healthcare’s “Interest Surges in Medicare Bundled Payment Initiative” article on July 31, 2014, enthusiasm for bundled pricing has been associated with the Medicare Bundled Payments for Care Improvement (BPCI) initiative, which has consisted principally of cardiac and orthopedic procedures with a hospital inpatient component.
read article 

Cancer Research UK, Cancer Research Technology and Asterias Biotherapeutics Partner to Trial Immunotherapy Vaccine For Lung Cancer

(CNNMoney) Sept 11, 2014 – Cancer Research UK and Cancer Research Technology (CRT) have reached an agreement with Asterias Biotherapeutics, Inc. to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.
read article 

The 'Family Business' Behind the Flurry of PD-1 Inhibitors

(Medscape Medical News) Sept 10, 2014 - Discoveries from a duo of scientists at the Dana-Farber Cancer Center and Harvard Medical School have contributed to understanding how tumors hijack the PD-1 pathway and evade immune recognition.
read article (free registration required) 

J.P. Morgan's Dimon Finishes Scheduled Cancer Treatments

(Wall Street Journal) Sept 11, 2014 - In the days after J.P. Morgan Chase & Co. chief James Dimon disclosed he had throat cancer, the 58-year old executive received an email from Warren Buffett.
read article (paid subscription required) 

The Big Issues Affecting Lung Cancer Worldwide

(Cancer Research UK/Science Blog) Sept 11, 2014 - We’ve teamed up with the journal Nature, which today publishes a series of articles that touch on some key areas for lung cancer – from research to prevention – from across the globe.
read article 

7 Threats to Cancer Care

(Medscape Medical News) Sept 10, 2014 – Separate reports from ASCO and the ACCC outline a series of threats to the way cancer care is currently being delivered in the United States - the experts weigh in.
read article (free registration required) 

Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in FGF-aberrant Advanced Breast Cancer

(Yahoo! Finance) Sept 10, 2014 - Clovis Oncology today announced that its Phase 2 study of lucitanib in patients with FGF-aberrant, advanced breast cancer has commenced and the first patient dosed at a U.S. study site.
read article 

MOLOGEN AG: Initiation of Phase III IMPALA Study With Immunotherapy MGN1703 in Colorectal Cancer

(MOLOGEN) Sept 11, 2014 - MOLOGEN AG has enrolled the first patient in the international IMPALA study. Primary objective of the phase III pivotal trial is to prove that a switch maintenance therapy with the cancer immunotherapy MGN1703 leads to an increased overall survival (OS) in patients with metastatic colorectal carcinoma.
read corporate press release 

Penn Study Finds Genetic Mutations Linked With Ethnic Disparities in Cancer

(Penn News) Sept 9, 2014 - One of the goals of genome sequencing is to identify genetic mutations associated with increased susceptibility to disease.
read article 

Random Biopsy on Negative Colposcopy Detects More Disease

(Medscape Medical News) Sept 10, 2014 - A single random biopsy at the transformation zone increases the detection rate of high-grade cervical disease by approximately 20% in women who have a negative colposcopy, a new post hoc analysis shows.
read article (free registration required) 

Genomic Analysis Reveals That a High-Risk Leukemia Subtype Becomes More Common With Age

(St. Jude) Sept 10, 2014 – Stage set to determine if drugs called tyrosine kinase inhibitors will extend the lives of patients with the high-risk acute lymphoblastic leukemia subtype; pediatric clinical trial scheduled to open by early 2015.
read press release 

What Cancer Patients Want and What Medicare Covers May Differ

(Reuters Health) Sept 10, 2014 - When asked what Medicare should cover for cancer patients in their last months of life, many patients and their caregivers choose benefits the federal insurance does not offer, like home-based long term care and concurrent palliative care, according to a new study based on interviews.
read article 

U.S. FDA Approves Expanded Use of Medivation Prostate Cancer Drug

(Reuters) Sept 10, 2014 - U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.
read article 

FDA Advisors: No to Nebivolol/Valsartan Combo Pill for HTN

(Medscape Medical News) Sept 10, 2014 - An FDA advisory panel has recommended by a six-to-four vote that a dual-agent medication combining a beta-blocker and an angiotensin-receptor blocker (ARB) not be approved for the treatment of hypertension.
read article (free registration required) 

University Plan to Review Clinical Trial Work Meets Conflict Charges

(Wall Street Journal/Pharmalot blog) Sept 10, 2014 - Hiring the Association for the Accreditation of Human Research Protection Programs to review clinical trial practices is proving controversial for the University of Minnesota.
read article (paid subscription required) 

FDA Staff Review of NPS Drug Sparks Stock Rebound

(Reuters) Sept 10, 2014 - NPS Pharmaceuticals Inc's hormone replacement therapy Natpara appears effective, though data from one clinical trial site was excluded due to manufacturing violations, according to a preliminary report by the U.S. Food and Drug Administration.
read article 

A New Cancer Drug Worked In Over 25% Of Patients In A Phase I Trial

(Forbes) Sept 10, 2014 - The new cancer drug CPI-613, made by Cornerstone Pharmaceuticals, benefited 29 percent of cancer patients during a phase I trial at Wake Forest Baptist Medical Center, even putting one patient with myelodysplastic syndrome in a complete remission that has lasted for more than three years.
read article 

ASH Comments on Proposals Covering Medicare Payments to Physicians and Hospitals in 2015

(ASH) Sept 9, 2014 - On August 29, 2014, ASH submitted comment letters covering Medicare proposals for payments and associated policies for services paid under the physician fee schedule and the hospital outpatient prospective payment system. ASH analyzed the physician fee schedule and hospital outpatient rule when they were released in July.
read article 

Workshop: Innovations in Breast Cancer Drug Development

(ASCO in Action) Sept 9, 2014 - ASCO, the U.S. Food and Drug Administration, the American Association for Cancer Research, and the Breast Cancer Research Foundation are sponsoring a public Breast Cancer Workshop on Oct. 21, 2014, at the Hyatt Regency Bethesda in Bethesda, Maryland.
read article 

CancerLinQ™ Receives Major Commitment from CTCA®

(ASCO in Action) Sept 9, 2014 - The Conquer Cancer Foundation of ASCO has received a major commitment of support for the development of CancerLinQ™ from Cancer Treatment Centers of America, Inc. (CTCA), a national network of five cancer hospitals.
read article 

Louis J. DeGennaro, Ph.D., Named President and Chief Executive Officer of The Leukemia & Lymphoma Society

( Sept 9, 2014 - The Leukemia & Lymphoma Society (LLS) announced today that Louis J. DeGennaro, Ph.D., has been appointed as president and chief executive officer, effective immediately.
read press release